about
Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner HippiGender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infectionAge-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington diseaseSatellog: a database for the identification and prioritization of satellite repeats in disease association studies.Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's DiseaseIron dysregulation in Huntington's diseaseDetection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling.Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse modelHuntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genesHIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosisCompensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyThe advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease miceHuntingtin inhibits caspase-3 activationNeurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysisClinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.Expression analysis of novel striatal-enriched genes in Huntington disease.Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.Huntington disease: natural history, biomarkers and prospects for therapeutics.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.CAG-encoded polyglutamine length polymorphism in the human genomeBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease.Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysisFull-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expressionDevelopment of biomarkers for Huntington's disease.Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseRole of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical PerformanceA Computational Cognitive Biomarker for Early-Stage Huntington's Disease.Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.8OHdG is not a biomarker for Huntington disease state or progressionBrain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease
P50
Q24292161-8495927A-7EC3-4A0F-A87E-0A1F20C0B708Q24651348-E70EFA7F-C990-4C96-A00B-51E31F7A66D3Q24657764-D27A82C2-1F27-41BC-A18B-3F817A554962Q24815425-9F58A0CD-7910-4068-94A6-C946CA89F419Q26781849-1832EA1E-91AD-4F03-8FB6-7BE479B032EBQ26829932-84BADADB-96A2-468C-BFA4-53BCA3D0B793Q27317122-6840854E-50C1-42D0-95B2-5415C7CCFEF3Q27324722-395A22B1-8738-4A08-A3D1-A0C74740598CQ28189644-45E9C985-53C9-4957-8F6D-A86BC970A838Q28209859-D5A2009C-3C12-43A2-8579-45E278B751FFQ28393234-5D77A744-62EE-4D6C-89DE-193715451182Q28485924-B4929CC8-23E7-407B-895B-E6918985BD98Q28507134-F6CB780D-C107-4CC9-B11A-B828652F1F6DQ28566357-3238C9AB-64D6-4FF5-82AD-41DF9477B3ECQ30224292-AE2B83EF-D646-4D0B-8E51-73F2137DC04CQ30278084-36BC8FF1-277E-4D22-B70E-0DF2CEC88D07Q30315395-7BBCC0C2-F8DC-4632-8B11-A6C1471D7F5EQ30476999-858CFE43-E443-4BE9-9ACA-B3E462D15A8DQ30624346-4D5C014D-D8FA-4EED-B32C-736648698107Q30774172-D7106E36-6B0F-4BEE-B387-2B334A8311EDQ31002507-3712E05B-2163-4BAD-91DC-645BC72CB198Q33255969-F1AE39CE-BB71-4330-89F0-F96EF4F972F5Q33265508-23EF2E8C-6260-4416-A897-80336E9BCCA1Q33285435-DD49249C-CBD3-4500-91CA-726AA7D3AD8AQ33489152-7236B18B-7772-4457-A42E-7EB8D7277435Q33579030-494DB6A3-FE9B-487B-92FD-4A079CDCFC6BQ33755822-00D85218-83C7-431B-A3CF-9A095E88F810Q33755845-0274BE06-2382-421C-AF7E-E9010392B1A8Q33907629-F9C2F661-374F-4DF6-A0B9-E989074B0949Q33914031-A94592DA-4CEC-4485-94A6-2DFAAF5483DEQ34089875-343CD0BD-0ADF-479E-BE64-6FF18DAFF565Q34470414-EA1B88AD-DFB7-4659-B179-FFC1A585738AQ34634976-54BA4426-B544-44AC-9C1D-1C7B9733052EQ34795840-18A5C8F0-12A9-48E8-AC22-E8F2441FE89CQ35595444-2F3ED1E6-4105-4CA4-90B7-5A88687C54E6Q35906778-1F9E9905-3045-4840-83FF-CE27F2742F8FQ35922437-6BEB6ED7-1322-45C9-89BB-0DAE200F156FQ36011977-514230B5-FB26-4BE7-B466-C9A8B484052DQ37027144-62C83B49-852B-4579-BB1B-D8AD2AFB952FQ37113861-D6DB1ECA-3132-496D-83A4-8CB5C1DA97DF
P50
name
Blair R Leavitt
@en
type
label
Blair R Leavitt
@en
prefLabel
Blair R Leavitt
@en